Molecular Pathology of Cancer Group

2024 Activity indicators

  • 4 national public competitive projects: ISCIII
  • 2 private competitive projects led
  • 5 private projects led
  • 158 clinical led trials
  • 71 publications
  • IF: 664.00
  • Q1 publications: 50 (70%)
  • D1 publications : 28 (39%)
  • 1 thesis
  • 1 consensus document 
  • 5 acknowledgements to group members
  • Evaluators of national public agency projects: 1 PI
  • Members of national and international editorial committees: 1 PI
  • 3 visitors hosted and 6.3 months stay:
    • Universidad Politécnica de Madrid (spain)
    • University Chieti-Pescara (Italy)

Milestones

  1. Coordination of the Breast Pathology Unit of the HURYC, contributing to obtaining its re-accreditation.
  2. Participation in the consensus guide for the use of biomarkers in breast cancer "Colomer R, GonzálezFarré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2024; 26(12):2935-2951. doi: 10.1007/s12094-024-03541-1. PMID: 38869741".
  3. Stabilization of the cervical cancer screening program of the Community of Madrid (CERVICAM) and of the NGS project in solid tumors (ROM).
  4. Optimization of single-cell RNA seq in tissue fixed in formol and included in paraffin.
  5. Participation in collaborative research networks in cancer within the framework of CIBERONC.

Bibliometrics

  Article Accum. FI Mean FI  Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % on D1
2020 17 69.25 4.07 12 71 5 29
2021 17 102.25 6.01 13 76 2 12
2022 25 149.83 5.99 18 72 6 24
2023 41 354.21 10.42 27 66 7 17
2024 71 664.00 10.38 61 86 28 39
  171 1339.54 7.38 131 77 48 28

* Only original articles, editorials, guidelines & reviews

Networks and alliances